Int J Curr Pharm Res, Vol 11, Issue 5, 72-75Original Article


DEVELOPMENT AND VALIDATION OF A SIMPLE UV SPECTROPHOTOMETRIC METHOD FOR THE ESTIMATION OF SALBUTAMOL SULPHATE FROM PHARMACEUTICAL FORMULATIONS

G. R. GADEKAR1*, S. S PATIL, R. R. SHAH, D. S. GHODKE

Department of Pharmaceutics, Appasaheb Birnale College of Pharmacy, South-Shivaji Nagar, Sangli-Miraj Road, Sangli 416416, India
Email: gadekarganesh@gmail.com

Received: 18 May 2019, Revised and Accepted: 15 Jul 2019


ABSTRACT

Objective: The present study was undertaken to develop a rapid, simple, specific and economic ultraviolet (UV) spectrophotometric method for estimating the Salbutamol Sulphate (SS) in pharmaceutical formulations.

Methods: The analysis was performed at λ max 276 nm using Sorenson’s isotonic phosphate buffer pH 7 (SIPB pH 7) as blank/diluent. The method was validated by following the analytical performance parameters as suggested by International Conference on Harmonization (ICH) which included accuracy, precision, linearity.

Results: The drug follows the beer’s lambert’s law in the concentration range of 12.5-37.5μg/ml and exhibited good correlation coefficient (0.9997) and excellent mean recovery. Percentage RSD for precision and accuracy of the method was found to be less than 2%. This method was successfully applied for the determination of the Salbutamol Sulphate in commercial brands of Indian market and the results were in good agreement with the label claims. The developed method was suitable and specific to the analysis of Salbutamol Sulphate even in the presence of common excipients.

Conclusion: The obtained results proved that the validated method can be employed for the routine analysis of Salbutamol Sulphate in bulk as well as in the commercial formulations.

Keywords: Salbutamol sulphate, UV Spectrophotometric method, Validation, Sorenson’s isotonic phosphate buffer pH 7


INTRODUCTION

Salbutamol, RS-[4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxylmethyl) phenol] is a short-acting β2-adrenergic receptor agonist used for the relief of Broncho-spasm in conditions such as asthma and chronic obstructive pulmonary disease. Salbutamol is still commonly delivered as a racemic mixture (+,-). Salbutamol, even though S-Salbutamol is known to have a detrimental effect on asthma sufferers (in fact the exact opposite effect of the R Isomer). The mechanism of action involves the relaxation of bronchial smooth muscle by stimulating the β2 adrenergic receptors. It is official in pharmacopoeia. Therefore a rapid, economic and selective method is needed, for the routine quality control analysis of pharmaceutical formulations containing salbutamol sulphate. The analysis was performed on λ max 276 nm using Sorenson’s isotonic phosphate buffer pH 7 (SIPB pH 7) as blank/diluent. Salbutamol is available in tablets, capsules and aerosol inhalers [1].

This paper describes UV spectrophotometric method for the estimation of salbutamol sulfate from pharmaceutical formulations.

MATERIALS AND METHODS

UV-Visible spectrophotometer used in the experiment was from JASCO-550, Japan UV-Visible Double Beam Spectrophotometer. All other chemicals were used are of Laboratory grade.

Materials

Table 1 shows the list of materials obtained as a gift sample as well as purchased from commercial sources for the experimental work of this study.

Table 1: List of materials and chemicals

Name of the material/Chemical Obtained/Purchased
Salbutamol sulphate (SS) Medioral Labs Ltd, Additional MIDC, Satara, Maharashtra, India.
Water soluble chitosan (WSC) Marine chemicals, Cochin, Kerala, India.
Pluronic F-127 Sigma-Aldrich Chemicals.
Monobasic Sodium phosphate (NaH2PO4). H2O Merck Specialties, Mumbai.
Dibasic Sodium Phosphate (Na2HPO4) Loba Chemicals, Bombay.
Sodium Chloride (Extra pure) Otto Kemi, Mumbai.
Acetone (HPLC and Spectroscopy grade) Research Lab Fine chem., Mumbai.
N,N-Dimethyl formamide Thomas Baker chem. Ltd., Mumbai.
KBr Loba Chemicals, Bombay.

Method development

Various dissolution Medias were tested for the development of a suitable dissolution method for the dissolution study of Salbutamol Sulphate dry powder inhaler for pulmonary delivery. At last the following Medium was selected [2].

Medium: Sorenson’s isotonic phosphate buffer pH 7 (SIPB pH 7)

Mix 40 ml of 0.0667 M Monobasic Sodium phosphate dihydrate (NaH2PO4.2H2O) and 60 ml of 0.0667 M Dibasic Sodium phosphate anhydrous (Na2HPO4) the resulting pH will be 7. Sodium chloride (0.46 g/100 ml) will be required for isotonicity.

Accurately weighed and transferred about 25 mg of Salbutamol Sulphate working standard into a 100 ml volumetric flask. Added about 50 ml of SIPB pH 7 and dissolved by shaking and made up the volume with SIPB pH 7 to prepare a stock solution of concentration 250 μg/ml. From the above stock solution of concentration of 250 μg/ml serial dilutions were done as mentioned in the table 2 and the absorbance of various dilutions was measured against SIPB pH 7 as a blank at 276 nm using the JASCO-550, UV-Visible Spectrophotometer. The graph of absorbance versus concentration was plotted to get the calibration curve. Obtained data were subjected for linear regression analysis in Microsoft excel.

Table 2: Serial dilutions of salbutamol sulphate

S. No. ml withdrawn from stock solution Diluted up to (ml) Concentration μg/ml
1 0.5 10 12.5
2 1 10 25
3 1.5 10 37.5
4 2 10 5
5 2.5 10 67.5
6 3 10 75
7 3.5 10 87.5
8 4 10 100
9 4.5 10 112.5
10 5 10 125

Twenty tablets of marketed tablet formulation of Salbutamol Sulphate were weighed; their average weights determined and were finely powdered. The correct amount of powder equivalent to 5 mg SS was accurately weighed and dissolved in 50 ml SIPB 7 to prepare a stock solution of concentration 100 μg/ml. The excipients were separated by filtration. After filtration, appropriate aliquots were subjected for assay and the amount of Salbutamol sulphate was determined.

Method validation [3-6]

Specificity

Scanning and absorbance measurement carried out for the blank (diluents used in the method) and test solution

Precision was determined at three levels i.e. repeatability, Intermediate precision, reproducibility. Repeatability is given as inter and intra-day precision concentrations of Salbutamol Sulphate.

Table 3: Recommended levels of precision

Component measured in a sample Precision
≥ 10.0% ≤ 2%
1.0 up to 10.0% ≤ 5%
0.1 up to 1.0% ≤ 10%
<0.1% ≤ 20%

The concentrations of Salbutamol Sulphate from 12.5-125 μg/ml were prepared from the stock solution (250 μg/ml) and absorbance of measured at 276 nm. The graph was plotted between concentration and absorbance for linearity.

The detection limit of an analytical procedure is the lowest amount of an analyte in a sample that can be detected, but not necessarily quantitated as an exact value. The LOD may be determined by the analysis of samples with known concentrations of analyte and by establishing the minimum level (lowest calibration standard) at which the analyte can be reliably detected.

Based on the standard deviation of the response and the slope

The detection limit (DL) may be expressed as:

Where, σ = the standard deviation of the response

S = the slope of the calibration curve the slope S may be estimated from the calibration curve of the analyte. The estimate of σ may be carried out.

Based on the calibration curve

A specific calibration curve should be studied using samples, containing an analyte in the range of DL. The residual standard deviation of a regression line or the standard deviation of y-intercepts of regression lines was used as the standard deviation.

The limit of quantitation is the lowest amount of the analyte in the sample that can be quantitatively determined with defined precision under the stated experimental conditions.

Based on the standard deviation of the response and the slope

The quantitation limit (QL) may be expressed as:

Where, σ = the standard deviation of the response

S = the slope of the calibration curve

The slope S may be estimated from the calibration curve of the analyte. The estimate of σ may be carried out.

Based on the calibration curve

A specific calibration curve should be studied using samples, containing an analyte in the range of QL. The residual standard deviation of a regression line or the standard deviation of y-intercepts of regression lines was used as the standard deviation.

Standard addition method: in the standard addition method, the sample of Salbutamol sulphate was assayed, a known amount of pure active Salbutamol sulphate constituent was added in test solution and the sample was again assayed in triplicate. And recovery of the drug was determined in formulation.

To check the accuracy of the developed method and to study the interference of formulation additives, analytical recovery experiments were carried out by standard addition method, at 50,

100 and 150 % level. From the total amount of drug found, the percentage recovery was calculated. Acceptance criteria: the expected recovery depends on the sample matrix, the sample processing procedure and on the analyte concentration. The mean % recovery should be within the following ranges:

Salbutamol sulfate contains not less than 98.0% and not more than 101.0% of, (C13H21NO3)2. H2SO4 calculated with reference to the dried substance.

RESULTS AND DISCUSSION

The proposed UV spectroscopic method has been developed for the determination of salbutamol sulphate from pharmaceutical formulations.

The maximum absorbance λ of salbutamol sulphate in Sorenson’s isotonic phosphate buffer pH 7 was found to be 276 nm. The drug follows the beer’s lambert’s law in the concentration range of 12.5-37.5μg/ml. The proposed method of determination of salbutamol sulphate showed molar absorptivity is 3499.2054 L. mol-1. cm-1. Linear regression of absorbance on concentration with the equation Y=0.00608X-0.00478 with correlation coefficient of 0.9997. The applicability to proposed method for the assay of Salbutamol sulphate in pharmaceutical formulation was examined by analyzing commercial formulations and the results were tabulated in table.

Accuracy was performed by recovery studies. The % recovery value indicates that there is no interference from the excipients present in the formulation. The recovery studies are presented in the table.

Table 4: Assay result of the marketed formulation of salbutamol sulphate

Marketed formulation Label claim (mg) Amount obtained (mg) Percent purity
Asthalin-2 Tablet 2.4 2.38 99.16

Table 5: Recovery of salbutamol sulphate using proposed UV method

S. No. Amount of drug added (mg) Amount present Mean (±) Amount % of the recovery
1 0.125 0.373 99.46
2 0.250 0.496 99.20
3 0.375 0.624 99.84

Table 6: Optical characteristic of salbutamol sulphate

Absorption maxima (nm) 276
Beer's law limit (mcg/ml) 12.5-37.5
Correlation coefficient 0.99979
Molar absorptivity (lit/mole/cm) 3499.205462
Sandell's sensitivity (mcg/Sq. cm/0.001) 0.164809

Regression equation

Slope (m)

Intercept

0.006068

-0.00478

% COV 1.219404
Confidence limit with 0.05 level 0.00478
LOD 1.349219
LOQ 4.088543

Table 7: Precision interday

S. No. Concentration () Absorbance Mean Standard deviation % RSD
I II III
1. 12.5 0.0797 0.0784 0.0777 0.0786 0.001015 1.291208
2. 25 0.1485 0.1444 0.1478 0.1469 0.002193 1.492969
3. 37.5 0.2285 0.2220 0.2263 0.2255 0.003279 1.453977
4. 50 0.3032 0.2929 0.3015 0.2992 0.005522 1.845513
5. 67.5 0.3800 0.3754 0.3822 0.3792 0.00347 0.91505
6. 75 0.4610 0.4576 0.4666 0.46173333 0.004545 0.984246

Table 8: Precision intraday

S. No. Concentration Absorbance Mean Standard deviation % RSD
I II III
1. 12.5 0.0735 0.0747 0.0744 0.0744 0.000874 1.1732
2. 25 0.1434 0.1435 0.1465 0.1444 0.00176 1.2194
3. 37.5 0.2189 0.2208 0.2185 0.2194 0.00122 0.5600
4. 50 0.2886 0.2970 0.2932 0.2929 0.00420 1.14359
5. 67.5 0.3772 0.3692 0.3800 0.3754 0.00560 1.4927
6. 75 0.4593 0.4526 0.4610 0.4576 0.00444 0.9704

AUTHORS CONTRIBUTIONS

All the author have contributed equally

CONFLICT OF INTERESTS

Declare none

REFERENCES

  1. Indian Pharmacopiea. Delhi: Controller of publications; 1996. p. 668-70.

  2. Healy A, Deirdre C, Owen C. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipients spray-dried mixtures for use in dry powder inhalers. Int J Pharm 2006;322:22-30.

  3. http://www.apvma.gov.au [Last accessed on 10 Apr 2019]

  4. ICH harmonized tripartite guideline: validation of analytical procedures: text and methodology Q2 (R1); 2005.

  5. Sonawane S, Shirkhedkar A, Fursule Ravindra A, Surana S. Application of UV spectrophotometry and RP-HPLC for simultaneous determination of atorvastatin calcium and ezetimibe in the pharmaceutical dosage form. Eurasian J Anal Chem 2006;1:31-41.

  6. Verma S, Alam O, Mullick P, Siddiqui N, Khan S. Validated, ultraviolet spectroscopy method for the dissolution study of mycophenolate mofetil immediate release 500 mg tablets. Nat Precedings Doi:10.1038/npre.2008.2250.